# US 2023/0398108 A1 · Pharmaceutical Compositions of a Kinase Inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398108 A1
- Document ID: US20230398108A1
- Status: Published application
- Kind: A1
- Application number: 18/035,355
- Filed: 2021-11-04
- Published: 2023-12-14
- Earliest claimed: 2020-11-05
- Assignees: Exelixis, lnc.
- Applicants: Exelixis, lnc.
- Inventors: Iswadi LIEJANTO; Tzu-Yuan CHEN
- Web page: https://patentgrep.com/patent/US20230398108A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2095: {Tabletting processes}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to pharmaceutical compositions of the c-Met inhibitor, Compound 1. The invention also relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase using the pharmaceutical composition and to processes for making the pharmaceutical compositions.

## Claims

### Claim 1

A pharmaceutical composition suitable for oral administration, comprising:
a. Compound 1, which has the structure:
or a pharmaceutically acceptable salt thereof;
b. one or more diluents;
c. one or more binders;
d. one or more disintegrants;
e. one or more glidants;
f. one or more lubricants; and optionally
g. a film coating.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, comprising:
a. Compound 1, or a pharmaceutically acceptable salt thereof;
b. one or more diluents selected from the group consisting an inorganic diluent, polysaccharide, mono- or disaccharide or sugar alcohol;
c. one or more binders selected from the group consisting of sodium carboxymethylcellulose, polyvinyl pyrrolidone (PVP), copovidone, polyvinyl pyrrolidone-vinyl acetate (PVP/VA) copolymer, hydroxypropylcellulose, hydroxypropyl methylcellulose and ethyl cellulose;
d. one or more disintegrants selected from the group consisting of croscarmellose sodium, crospovidone, low-substituted hydroxypropylcellulose or sodium starch glycolate;
e. one or more glidants;
f. one or more lubricants; and optionally
g. a film coating.

### Claim 3 (depends on 1, 2)

The pharmaceutical composition of claim 1 or 2, wherein the pharmaceutical composition is a capsule or tablet.

### Claim 4 (depends on 1, 2)

The pharmaceutical composition of claim 1 or 2, wherein the pharmaceutical composition is a capsule.

### Claim 5 (depends on 1, 2)

The pharmaceutical composition of claim 1 or 2, wherein the pharmaceutical composition is a tablet.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The pharmaceutical composition of any one of claims 1-5, containing about 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, or 120 mg of Compound 1 (free base equivalent).

### Claim 7 (depends on 1, 2, 3, 4, 5)

The pharmaceutical composition of any one of claims 1-5, containing at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% or 100% weight/weight (w/w) of Compound 1.

### Claim 8 (depends on 2)

The pharmaceutical composition of claim 2, comprising:
a. about 20 percent to about 40 percent by weight of Compound 1;
b. about 35 percent to about 45 percent by weight of microcrystalline cellulose;
c. about 15 to about 25 percent by weight of lactose;
d. about 2 to about 8 percent by weight of hydroxypropyl cellulose;
e. about 4 to about 8 percent by weight of croscarmellose sodium;
f. about 0.1 to about 0.5 percent by weight of silicon dioxide; and
g. about 0.5 to 3.5 percent by weight magnesium stearate; and optionally
h. a film coating.

### Claim 9 (depends on 2)

The pharmaceutical composition of claim 2, comprising:
a. about 20 percent to about 40 percent by weight of Compound 1;
b. about 35 percent to about 45 percent by weight of microcrystalline cellulose;
c. about 15 to about 25 percent by weight of lactose;
d. about 2 to about 8 percent by weight of hydroxypropyl cellulose;
e. about 2 to about 8 percent by weight of croscarmellose sodium;
f. about 0.1 to about 0.5 percent by weight of colloidal silicon dioxide; and
g. about 1 to 5 percent by weight of stearic acid; and optionally
h. a film coating.

### Claim 10 (depends on 2)

The pharmaceutical composition of claim 2, comprising:
a. about 15-150 mg of Compound 1 (free base equivalent);
b. microcrystalline cellulose;
c. lactose;
d. hydroxypropyl cellulose;
e. croscarmellose sodium;
f. silicon dioxide;
g. magnesium stearate or stearic acid; and optionally
h. a film coating.

### Claim 11 (depends on 2)

The pharmaceutical composition of claim 2, comprising:
a. about 20 mg of Compound 1 (free base equivalent);
b. about 30 to about 35 mg of microcrystalline cellulose;
c. about 15 to about 18 mg anhydrous lactose;
d. about 1.5 to about 4.5 mg hydroxypropyl cellulose;
e. about 4 to about 6 mg of croscarmellose sodium;
f. about 0.1 to about 0.3 mg colloidal silicon dioxide; and
g. about 0.5 to about 0.7 mg magnesium stearate; and optionally
h. about 2 to about 6 mg of a film coating.

### Claim 12 (depends on 2)

The pharmaceutical composition of claim 2, comprising:
a. about 80 mg of Compound 1 (free base equivalent);
b. about 120 to about 150 mg of microcrystalline cellulose;
c. about 60 to about 80 mg anhydrous lactose;
d. about 6 to about 18 mg hydroxypropyl cellulose;
e. about 15 to about 25 mg of croscarmellose sodium;
f. about 0.4 to about 1.5 mg colloidal silicon dioxide; and
g. about 2 to about 3 mg magnesium stearate; and optionally
h. about 8 to about 26 mg of a film coating.

### Claim 13 (depends on 2)

The pharmaceutical composition of claim 2, comprising:
a. about 20 mg of Compound 1 (free base equivalent);
b. about 30 to about 40 mg of microcrystalline cellulose;
c. about 15 to about 20 mg anhydrous lactose;
d. about 3 to about 7 mg hydroxypropyl cellulose;
e. about 3 to about 7 mg of croscarmellose sodium;
f. about 0.1 to about 0.3 mg colloidal silicon dioxide; and
g. about 2 to about 4 mg stearic acid; and optionally
h. about 2 to about 5 mg of a film coating.

### Claim 14 (depends on 2)

The pharmaceutical composition of claim 2, comprising:
a. about 40 mg of Compound 1 (free base equivalent);
b. about 50 to about 70 mg of microcrystalline cellulose;
c. about 25 to about 35 mg anhydrous lactose;
d. about 6 to about 10 mg hydroxypropyl cellulose;
e. about 6 to about 10 mg of croscarmellose sodium;
f. about 0.2 to about 0.6 mg colloidal silicon dioxide; and
g. about 4 to about 8 mg stearic acid; and optionally
h. about 4 to about 10 mg of a film coating.

### Claim 15 (depends on 2)

The pharmaceutical composition of claim 2, comprising:
a. about 60 mg of Compound 1 (free base equivalent);
b. about 80 to about 120 mg of microcrystalline cellulose;
c. about 40 to about 70 mg anhydrous lactose;
d. about 12 to about 15 mg hydroxypropyl cellulose;
e. about 12 to about 15 mg of croscarmellose sodium;
f. about 0.5 to about 0.8 mg colloidal silicon dioxide; and
g. about 6 to about 12 mg stearic acid; and optionally
h. about 6 to about 12 mg of a film coating.

### Claim 16 (depends on 2)

The pharmaceutical composition of claim 2, comprising:
a. about 80 mg of Compound 1 (free base equivalent);
b. about 120 to about 150 mg of microcrystalline cellulose;
c. about 60 to about 80 mg anhydrous lactose;
d. about 12 to about 30 mg hydroxypropyl cellulose;
e. about 12 to about 30 mg of croscarmellose sodium;
f. about 0.5 to about 1.5 mg colloidal silicon dioxide; and
g. about 8 to about 16 mg stearic acid; and optionally
h. about 8 to about 14 mg of a film coating.

### Claim 17 (depends on 2)

The pharmaceutical composition of claim 2, comprising:
a. about 100 mg of Compound 1 (free base equivalent);
b. about 140 to about 160 mg of microcrystalline cellulose;
c. about 70 to about 90 mg anhydrous lactose;
d. about 15 to about 25 mg hydroxypropyl cellulose;
e. about 20 to about 30 mg of croscarmellose sodium;
f. about 0.8 to about 2.0 mg colloidal silicon dioxide; and
g. about 9 to about 18 mg stearic acid; and optionally
h. about 10 to about 30 mg of a film coating.

### Claim 18 (depends on 2)

The pharmaceutical composition of claim 2, comprising:
a. about 120 mg of Compound 1 (free base equivalent);
b. about 165 to about 195 mg of microcrystalline cellulose;
c. about 80 to about 100 mg anhydrous lactose;
d. about 20 to about 30 mg hydroxypropyl cellulose;
e. about 25 to about 35 mg of croscarmellose sodium;
f. about 1.0 to about 2.5 mg colloidal silicon dioxide; and
g. about 10 to about 20 mg stearic acid; and optionally
h. about 15 to about 35 mg of a film coating.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The pharmaceutical composition of any one of claims 1-18, wherein Compound 1 is a crystalline (freebase) solid or a crystalline pharmaceutically acceptable salt.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein Compound 1 is a crystalline solid form selected from Form A, B, C, D, E, F, G, H, J, K, O, or Q.

### Claim 21 (depends on 19)

The pharmaceutical composition of claim 19, wherein Compound 1 is a crystalline pharmaceutically acceptable salt selected from the group consisting of Compound 1 HCl salt, Compound 1 fumaric acid salt, and Compound 1 phosphoric acid salt.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the Compound 1 HCl salt is selected from the crystalline salt forms Compound 1 HCl salt Forms A, B, C, and D.

### Claim 23 (depends on 21)

The pharmaceutical composition of claim 21, wherein the Compound 1 fumaric acid salt is selected from the crystalline salt forms Compound 1 fumaric acid Form A and Compound 1 hemifumarate Form B.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, wherein the Compound 1 fumaric acid salt is Compound 1 hemifumarate Form B.

### Claim 25 (depends on 21)

The pharmaceutical composition of claim 21, wherein the Compound 1 phosphoric acid salt form is crystalline Compound 1 phosphoric acid salt form A.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method of treating a proliferative disease or disorder in a patient in need of such treatment, comprising administering to the patient the pharmaceutical composition of any one of claims 1-25.

### Claim 27 (depends on 26)

The method of claim 26, wherein the proliferative disease or disorder is cancer.

### Claim 28 (depends on 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A process of making a tablet of the pharmaceutical composition of any one of claims 1-3 and 5-25, comprising de-lumping excipients; granulating a mixture comprising Compound 1, the excipients and water through high-shear granulation to produce wet granules; de-lumping the wet granules; drying the wet granules through a fluid bed dryer to afford dried granules; milling the dried granules to afford milled granules; blending the milled granules with a disintegrant and/or a glidant to afford blended granules; lubricating the blended granules by blending the blended granules with a lubricant to produce a lubricated blend; and compressing the lubricated blend to form the tablet.

### Claim 29 (depends on 28)

The process of claim 28, further comprising coating the tablet.

### Claim 30 (depends on 28, 29)

The process of claim 28 or 29, wherein the disintegrants and/or the glidants are croscarmellose sodium and colloidal silicon dioxide.

### Claim 31 (depends on 28, 29, 30)

The process of any of claims 28-30, wherein the lubricant is magnesium stearate.

### Claim 32 (depends on 28, 29, 30)

The process of any of claims 28-30, wherein the lubricant is stearic acid.
